Category: biotech

.Pro equity capital agency venBio has raised yet another half a billion bucks to acquire biotechs focusing on ailments along with unmet need. The $528

.After declaring a stage 3 launch based on beneficial midstage end results, iTeos as well as GSK are ultimately discussing the highlights from the stage

.Zevra Therapeutics’ unusual ailment drug appears to be on the road to authorization this autumn after getting the backing of an FDA advisory committee, although

.Otsuka Drug’s renal ailment drug has reached the primary endpoint of a phase 3 test through displaying in an interim analysis the reduction of clients’

.Bicara Rehabs and Zenas Biopharma have offered fresh incentive to the IPO market with filings that show what recently social biotechs might resemble in the

.Chief executive officer David Ricks can easily see the companies establishing outdoors tents at basecamp behind Eli Lilly in an effort to acquire a footing

.After rearing $213 million in 2023– some of the year’s biggest exclusive biotech shots– Tome Biosciences is actually helping make decreases.” Despite our very clear

.As biotechs seek to transform a new webpage in August, at least 3 companies have shed personnel in attempts to build on. First up is

.OncoC4 is actually taking AcroImmune– as well as its own internal professional manufacturing capabilities– under its wing in an all-stock merger.Each cancer biotechs were actually

.Zephyrm Bioscience is actually gusting toward the Hong Kong stock market, filing (PDF) for an IPO to stake period 3 tests of its cell therapy